Clinical trial · Observational
Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia
Venetoclax in Chronic Lymphocytic Leukemia Effectiveness and Real-life Treatment Management
NCT03415035CI-TRIAL-00119175VERONEcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate real-life effectiveness and use in participants starting venetoclax treatment for Chronic Lymphocytic Leukemia (CLL).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer - Chronic Lymphocytic Leukemia | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Patients with Chronic Lymphocytic Leukemia (CLL)
- description
- Patients with diagnosed CLL and eligible to venetoclax as per label
Primary outcomes (1)
- measure
- Best Response of Venetoclax in Participants with Chronic Lymphocytic Leukemia (CLL) up to 12 Months
- timeFrame
- Up to approximately 12 months
- description
- The best response is defined as the best response observed during the first year of study treatment among the possible responses to treatment: Complete Response (CR), CR with incomplete bone marrow recovery (CRi), nodular Partial Response (nPR), Partial Response (PR), Stable Disease (SD), or Disease Progression (DP).
Secondary outcomes (12)
- measure
- Time To Next Treatment
- timeFrame
- Up to approximately 48 months
- description
- The time to next treatment is defined as the time between the date of the first venetoclax intake and the date of the first next treatment intake after venetoclax discontinuation.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participants with diagnosed Chronic Lymphocytic Leukemia (CLL) and eligible for venetoclax as per label. * Participants for whom the physician has decided to initiate CLL treatment with venetoclax. * Participants the physician believes he can personally follow over all the study period. * Participants who have been informed verbally and in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control. Exclusion Criteria: \- Participating in a clinical trial with an investigative drug for CLL within 30 days prior to treatment initiation.
References
Publications (0)
Data not yet available
No reference posted for this study.